Dexcom Reports Second Quarter 2024 Financial Results, Updates Guidance, and Announces $750 Million Share Repurchase Program

Rhea-AI Summary

Dexcom reported its Q2 2024 financial results, with revenue growing 15% year-over-year to $1.004 billion. U.S. revenue grew 19% while international revenue increased 7%. GAAP operating income was $158.0 million, or 15.7% of revenue. The company updated its 2024 guidance, projecting revenue of $4.00-4.05 billion (11-13% organic growth). Dexcom also announced a $750 million share repurchase program.

Strategic highlights include launching Direct-to-Watch in the U.S. and international markets, securing coverage for Dexcom ONE in France for type 2 diabetes patients on basal insulin, and advancing pump connectivity with Insulet and Tandem Diabetes Care. However, CEO Kevin Sayer noted that execution did not meet their high standards, and the company is taking action to improve.

Positive

• Revenue grew 15% year-over-year to $1.004 billion
• U.S. revenue increased by 19%
• GAAP operating income improved to 15.7% of revenue, up 100 basis points from Q2 2023
• Non-GAAP operating income reached 19.5% of revenue, up 130 basis points from Q2 2023
• Launched Direct-to-Watch in U.S. and international markets
• Secured coverage for Dexcom ONE in France for type 2 diabetes patients on basal insulin
• Advanced pump connectivity with Insulet and Tandem Diabetes Care
• Announced $750 million share repurchase program

Negative

• International revenue growth slower at 7% year-over-year
• CEO acknowledged execution did not meet high standards
• Lowered Q3 2024 revenue guidance to $975 million to $1.00 billion (1-3% organic growth)

Insights

Financial Analyst

Dexcom's Q2 2024 results present a mixed picture. While revenue growth of 15% year-over-year to $1.004 billion is solid, it's slightly below the company's historical growth rates. The 19% U.S. revenue growth is encouraging, but international growth at 7% (or 10% organic) suggests challenges in global markets.

The company's profitability metrics show improvement. GAAP operating income margin increased by 100 basis points to 15.7%, while non-GAAP operating income margin rose 130 basis points to 19.5%. This indicates better cost management and operational efficiency.

However, the updated guidance and newly introduced Q3 forecast raise concerns. The full-year organic growth expectation of 11-13% and Q3 organic growth of just 1-3% suggest a significant slowdown. This could be due to market saturation, increased competition, or macroeconomic headwinds.

The $750 million share repurchase program is a positive signal, indicating management's confidence in the company's long-term prospects and an effort to return value to shareholders. However, it might also suggest growth opportunities for reinvestment.

Overall, while Dexcom remains profitable and growing, the deceleration in growth rates and cautious guidance warrant close monitoring of future quarters' performance.

Medical Device Industry Expert

Dexcom's Q2 results highlight both progress and challenges in the continuous glucose monitoring (CGM) market. The launch of Direct-to-Watch functionality for G7 users is a significant advancement, potentially improving user experience and device adoption. This feature could be particularly appealing to tech-savvy users and may help Dexcom maintain its competitive edge.

The expanded coverage for Dexcom ONE in France for type 2 diabetes patients using basal insulin is a important development. It opens up a substantial new market segment, as type 2 diabetes is far more prevalent than type 1. This could drive significant volume growth in the coming quarters.

Integration with Insulet's Omnipod 5 and Tandem's Mobi pump strengthens Dexcom's position in the automated insulin delivery ecosystem. These partnerships are vital for maintaining market share in the face of increasing competition.

However, CEO Kevin Sayer's admission that execution didn't meet their high standards is concerning. It suggests internal operational issues that need addressing, which could explain the conservative guidance for Q3 and full-year 2024.

The real-world data presented at the American Diabetes Association conference demonstrating benefits for type 2 diabetes patients not on insulin is promising. If this leads to expanded indications and coverage, it could open up an enormous new market for Dexcom's products.

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2024.

Second Quarter 2024 Financial Highlights:

• Revenue grew 15% year-over-year to $1.004 billion on a reported basis and 16% year-over-year on an organic¹ basis.
• U.S. revenue grew 19% and international revenue grew 7% on a reported basis and 10% on an organic¹ basis, all on a year-over-year basis.
• GAAP operating income of $158.0 million or 15.7% of revenue, an increase of 100 basis points compared to the second quarter of 2023. Non-GAAP operating income* of $195.4 million or 19.5% of reported revenue, an increase of 130 basis points compared to the second quarter of 2023.

Second Quarter 2024 Strategic Highlights:

• Launched Direct-to-Watch in the U.S. and several international markets, providing G7 customers the option to use an Apple Watch as their primary display for glucose readings
• Secured coverage for Dexcom ONE in France for people with type 2 diabetes using basal insulin only, further expanding reimbursed access for real-time CGM in this market
• Advanced pump connectivity with the integration of Dexcom G7 to Insulet’s Omnipod 5 Automated Insulin Delivery System and Tandem Diabetes Care’s Mobi insulin pump with Control-IQ technology
• Showcased extensive clinical evidence at the American Diabetes Association’s 84th Scientific Sessions, including new real-world data demonstrating the benefit of Dexcom CGM for people with type 2 diabetes not on insulin

“While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards,” said Kevin Sayer, Dexcom’s chairman, president and CEO. “We have a unique opportunity to serve millions of more customers around the world with our differentiated product portfolio and we are taking action to improve our execution and best position ourselves for continued long-term growth.”

_________________________
1		Second quarter 2024 organic revenue was $1.005 billion and excludes $0.8 million of foreign exchange impact and $0.2 million of non-CGM revenue acquired or divested in the trailing twelve months. Second quarter 2023 reported revenue included $7.6 million of non-CGM revenue subsequently divested in the following twelve months.

Third Quarter and 2024 Annual Guidance and $750 Million Share Repurchase Program

Dexcom is updating fiscal year 2024 guidance for Revenue and Non-GAAP Gross Profit Margin, and reiterating guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin at the following levels:

• Revenue of approximately $4.00 - 4.05 billion (11 - 13% organic growth²)
• Non-GAAP Gross Profit Margin of approximately 63%
• Non-GAAP Operating Margin of approximately 20%
• Adjusted EBITDA Margin of approximately 29%

In addition, to account for certain unique items impacting 2024 seasonality, the company is establishing guidance for third quarter 2024 Revenue of approximately $975 million to $1.00 billion (1 - 3% organic growth).

The company also announced a $750 million share repurchase program in conjunction with second quarter results.

Second Quarter 2024 Financial Results

Revenue: In the second quarter of 2024, worldwide revenue grew 15% to $1.004 billion on a reported basis, up from $871.3 million in the second quarter of 2023. Volume growth in conjunction with strong new customer additions continues to be the primary driver of revenue growth as awareness of real-time CGM increases.

Gross Profit: GAAP gross profit totaled $626.7 million or 62.4% of revenue for the second quarter of 2024, compared to $546.4 million or 62.7% of revenue in the second quarter of 2023.

Non-GAAP gross profit* totaled $638.1 million or 63.5% of reported revenue for the second quarter of 2024, compared to $553.5 million or 63.5% of reported revenue in the second quarter of 2023.

Operating Income: GAAP operating income for the second quarter of 2024 was $158.0 million, compared to GAAP operating income of $128.1 million for the second quarter of 2023.

Non-GAAP operating income* for the second quarter of 2024 was $195.4 million, compared to non-GAAP operating income of $158.4 million for the second quarter of 2023.

Net Income and Diluted Net Income Per Share: GAAP net income was $143.5 million, or $0.35 per diluted share, for the second quarter of 2024, compared to GAAP net income of $115.9 million, or $0.28 per diluted share, for the second quarter of 2023.

Non-GAAP net income* was $174.3 million, or $0.43 per diluted share, for the second quarter of 2024, compared to non-GAAP net income of $139.4 million, or $0.34 per diluted share, for the second quarter of 2023. The second quarter 2024 non-GAAP net income excludes $8.4 million of amortization of intangible assets, $9.9 million of business transition and related costs, $3.2 million of credits related to COVID-19, $22.3 million of intellectual property litigation costs, $1.8 million of loss from equity investments, and $8.4 million of tax adjustments.

Cash and Liquidity: As of June 30, 2024, Dexcom held $3.12 billion in cash, cash equivalents and marketable securities and our revolving credit facility remains undrawn. The cash balance represents significant financial and strategic flexibility as Dexcom continues to expand production capacity and explore new market opportunities.

_________________________
2		Organic growth excludes non-CGM revenue acquired or divested in the trailing twelve months, as well as the impact of foreign exchange. Dexcom's 2024 organic growth expectation excludes approximately $30 million of fiscal year 2023 revenue related to the divestiture of certain non-CGM assets.

* See Table E below for a reconciliation of these GAAP and non-GAAP financial measures.

Conference Call

Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com by navigating to “Events and Presentations,” and will be archived for future reference. To listen to the conference call, please dial (877) 344-3040 (U.S./Canada) or (646) 475-1647 (International) and use the confirmation ID “9430114” approximately five minutes prior to the start time.

Statement Regarding Use of Non-GAAP Financial Measures

This press release and the accompanying tables include non-GAAP financial measures. For a description of these non-GAAP financial measures, including the reasons management uses each measure, and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with generally accepted accounting principles in the United States (GAAP), please see the section titled “About Non-GAAP Financial Measures” below as well as the related Table E. We have not reconciled our organic revenue growth, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin estimates for fiscal year 2024, nor our organic revenue growth estimate for the third quarter of fiscal year 2024, because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, reconciliations of our organic revenue growth, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin estimates are not available without unreasonable effort.

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

Category: IR

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements that are not purely historical regarding Dexcom’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to Dexcom’s future operating results and financial position, including estimated Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin for fiscal year 2024, and expected growth rates as compared to the year ended December 31, 2023; estimated Revenue for the third quarter of fiscal year 2024 and the expected growth rate as compared to the third quarter of fiscal year 2023; and future expenses and investments. All forward-looking statements included in this press release are made as of the date of this press release, based on information currently available to Dexcom as of the date hereof. Forward-looking statements deal with future events and are therefore subject to various risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from Dexcom’s current expectations are more fully described in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Dexcom’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings filed with the Securities and Exchange Commission. Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this communication or to conform these forward-looking statements to actual results.

DexCom, Inc.
Table A
Consolidated Balance Sheets
(In millions, except par value data)
		June 30, 2024				December 31, 2023
Assets
Current assets:
Cash and cash equivalents		$	939.2			$	566.3
Short-term marketable securities			2,181.5				2,157.8
Accounts receivable, net			945.2				973.9
Inventory			570.3				559.6
Prepaid and other current assets			212.2				168.3
Total current assets			4,848.4				4,425.9
Property and equipment, net			1,183.1				1,113.1
Operating lease right-of-use assets			71.2				71.4
Goodwill			23.3				25.2
Intangibles, net			114.5				134.5
Deferred tax assets			475.8				419.4
Other assets			82.9				75.0
Total assets		$	6,799.2			$	6,264.5
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued liabilities		$	1,569.8			$	1,345.5
Accrued payroll and related expenses			116.1				171.0
Short-term operating lease liabilities			21.6				21.1
Deferred revenue			14.7				18.4
Total current liabilities			1,722.2				1,556.0
Long-term senior convertible notes			2,437.8				2,434.2
Long-term operating lease liabilities			76.8				80.1
Other long-term liabilities			128.1				125.6
Total liabilities			4,364.9				4,195.9
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at June 30, 2024 and December 31, 2023			—				—
Common stock, $0.001 par value, 800.0 million shares authorized; 408.5 million and 400.7 million shares issued and outstanding, respectively, at June 30, 2024; and 407.2 million and 385.4 million shares issued and outstanding, respectively, at December 31, 2023			0.4				0.4
Additional paid-in capital			1,992.3				3,514.6
Accumulated other comprehensive loss			(38.0	)			(16.7	)
Retained earnings			1,311.3				1,021.4
Treasury stock, at cost; 7.8 million shares at June 30, 2024 and 21.8 million shares at December 31, 2023			(831.7	)			(2,451.1	)
Total stockholders’ equity			2,434.3				2,068.6
Total liabilities and stockholders’ equity		$	6,799.2			$	6,264.5

DexCom, Inc.
Table B
Consolidated Statements of Operations
(In millions, except per share data)
		Three Months Ended June 30,						Six Months Ended June 30,
		2024			2023			2024			2023
Revenue		$	1,004.3		$	871.3		$	1,925.3		$	1,612.8
Cost of sales			377.6			324.9			736.7			603.8
Gross profit			626.7			546.4			1,188.6			1,009.0
Operating expenses:
Research and development			136.0			119.3			277.5			238.3
Selling, general and administrative			332.7			299.0			652.0			595.4
Total operating expenses			468.7			418.3			929.5			833.7
Operating income			158.0			128.1			259.1			175.3
Other income (expense), net			29.8			31.2			61.2			48.5
Income before income taxes			187.8			159.3			320.3			223.8
Income tax expense			44.3			43.4			30.4			59.3
Net income		$	143.5		$	115.9		$	289.9		$	164.5
Basic net income per share		$	0.36		$	0.30		$	0.73		$	0.43
Shares used to compute basic net income per share			399.2			386.7			394.8			386.7
Diluted net income per share		$	0.35		$	0.28		$	0.71		$	0.40
Shares used to compute diluted net income per share			416.8			431.5			416.9			426.6

DexCom, Inc.
Table C
Revenue by Geography
(Dollars in millions)
(Unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
U.S. revenue		$	731.9			$	616.6			$	1,385.1			$	1,142.6
Year over year growth			19	%			21	%			21	%			19	%
% of total revenue			73	%			71	%			72	%			71	%
International revenue		$	272.4			$	254.7			$	540.2			$	470.2
Year over year growth			7	%			38	%			15	%			30	%
% of total revenue			27	%			29	%			28	%			29	%
Total revenue (1)		$	1,004.3			$	871.3			$	1,925.3			$	1,612.8
Year over year growth			15	%			25	%			19	%			22	%

(1)

The sum of the revenue components may not equal total revenue due to rounding.

DexCom, Inc.
Table D
Revenue by Component
(Dollars in millions)
(Unaudited)
	Three Months Ended June 30,								Six Months Ended June 30,
	2024				2023				2024				2023
Sensor and other revenue (1) (2)	$	947.0			$	778.0			$	1,801.3			$	1,429.9
Year over year growth		22	%			30	%			26	%			25	%
% of total revenue		94	%			89	%			94	%			89	%
Hardware revenue (1) (3)	$	57.3			$	93.3			$	124.0			$	182.9
Year over year growth		(39	)%			(5	)%			(32	)%			(1	)%
% of total revenue		6	%			11	%			6	%			11	%
Total revenue (4)	$	1,004.3			$	871.3			$	1,925.3			$	1,612.8
Year over year growth		15	%			25	%			19	%			22	%

(1)		Includes allocated subscription revenue.
(2)		Includes services, freight, accessories, non-CGM revenue, etc.
(3)		Includes transmitter and receiver revenue.
(4)		The sum of the revenue components may not equal total revenue due to rounding.

DexCom, Inc.
Table E
Itemized Reconciliation Between GAAP and Non-GAAP Financial Measures
(In millions, except per share data)
(Unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
GAAP gross profit		$	626.7			$	546.4			$	1,188.6			$	1,009.0
Amortization of intangible assets (1)			7.1				7.1				14.3				14.3
Business transition and related costs (2)			7.3				—				7.3				—
Credits related to COVID-19 (3)			(3.0	)			—				(3.0	)			—
Non-GAAP gross profit		$	638.1			$	553.5			$	1,207.2			$	1,023.3
GAAP operating income		$	158.0			$	128.1			$	259.1			$	175.3
Amortization of intangible assets (1)			8.4				8.8				18.8				17.8
Business transition and related costs (2)			9.9				0.7				13.4				1.8
Credits related to COVID-19 (3)			(3.2	)			—				(3.2	)			—
Intellectual property litigation costs (4)			22.3				20.8				47.5				42.1
Non-GAAP operating income		$	195.4			$	158.4			$	335.6			$	237.0
GAAP net income		$	143.5			$	115.9			$	289.9			$	164.5
Business transition and related costs (2)			9.8				0.6				13.2				1.6
Credits related to COVID-19 (3)			(3.2	)			—				(3.2	)			—
Depreciation and amortization			52.1				43.7				104.6				85.3
Intellectual property litigation costs (4)			22.3				20.8				47.5				42.1
Loss from equity investments (5)			1.8				—				1.8				—
Share-based compensation			44.7				39.7				83.7				74.9
Interest expense and interest income			(31.4	)			(31.5	)			(63.1	)			(49.2	)
Income tax expense			44.3				43.4				30.4				59.3
Adjusted EBITDA		$	283.9			$	232.6			$	504.8			$	378.5
GAAP net income		$	143.5			$	115.9			$	289.9			$	164.5
Amortization of intangible assets (1)			8.4				8.8				18.8				17.8
Business transition and related costs (2)			9.9				0.7				13.4				1.8
Credits related to COVID-19 (3)			(3.2	)			—				(3.2	)			—
Intellectual property litigation costs (4)			22.3				20.8				47.5				42.1
Loss from equity investments (5)			1.8				—				1.8				—
Adjustments related to taxes (6)			(8.4	)			(6.8	)			(65.7	)			(18.3	)
Non-GAAP net income		$	174.3			$	139.4			$	302.5			$	207.9

DexCom, Inc.
Table E (Continued)
Itemized Reconciliation Between GAAP and Non-GAAP Financial Measures
(In millions, except per share data)
(Unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
GAAP net income		$	143.5			$	115.9			$	289.9			$	164.5
Interest expense on senior convertible notes, net of tax			2.9				3.8				5.8				5.5
GAAP net income used for diluted EPS, if-converted (7)		$	146.4			$	119.7			$	295.7			$	170.0
Non-GAAP net income		$	174.3			$	139.4			$	302.5			$	207.9
Interest expense on senior convertible notes, net of tax			1.2				1.2				2.4				2.4
Non-GAAP net income used for diluted EPS, if-converted (7)		$	175.5			$	140.6			$	304.9			$	210.3
GAAP diluted net income per share (7)		$	0.35			$	0.28			$	0.71			$	0.40
Amortization of intangible assets (1)			0.02				0.02				0.05				0.04
Business transition and related costs (2)			0.02				—				0.03				—
Credits related to COVID-19 (3)			(0.01	)			—				(0.01	)			—
Intellectual property litigation costs (4)			0.05				0.05				0.12				0.10
Loss from equity investments (5)			—				—				—				—
Adjustments related to taxes (6)			(0.02	)			(0.02	)			(0.16	)			(0.04	)
Impact of adjustment to GAAP diluted shares (8)			—				0.01				—				—
Non-GAAP diluted net income per share (7) (9)		$	0.43			$	0.34			$	0.75			$	0.52
GAAP diluted weighted-average shares outstanding			416.8				431.5				416.9				426.6
Non-GAAP diluted weighted-average shares outstanding			409.1				407.8				409.2				407.7
Reconciliation of non-GAAP diluted weighted-average shares outstanding:
GAAP diluted weighted-average shares outstanding			416.8				431.5				416.9				426.6
Adjustment for dilutive impact of senior convertible notes due 2023 (10)			—				(18.9	)			—				(18.9	)
Adjustment for dilutive impact of senior convertible notes due 2028 (10)			(7.7	)			(4.8	)			(7.7	)			—
Non-GAAP diluted weighted-average shares outstanding			409.1				407.8				409.2				407.7

(1)		Represents amortization of acquired intangible assets.
(2)		For the three months ended June 30, 2024, business transition and related costs are primarily related to workforce reduction costs at our San Diego manufacturing facility and rent for vacated office space in San Diego, California. For the six months ended June 30, 2024, business transition and related costs are primarily related to the divestiture of certain non-CGM assets, workforce reduction costs, and rent for vacated office space in San Diego, California. For the three and six months ended June 30, 2023, business transition and related costs are primarily related to rent for vacated office space in San Diego, California.
(3)		Represents a credit received related to employment of personnel during the COVID-19 pandemic.
(4)		We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as further described in the section titled “Legal Proceedings” in Dexcom’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.
(5)		Represents losses from equity investments.
(6)		For the three months ended June 30, 2024, tax adjustments are primarily related to the tax effect of non-GAAP adjustments and excess tax benefits from share-based compensation for employees. For the six months ended June 30, 2024, tax adjustments are primarily related to the tax effect of the Verily milestone payment, non-GAAP adjustments, and excess tax benefits from share-based compensation for employees. For the three and six months ended June 30, 2023, tax adjustments are primarily related to the tax effect of non-GAAP adjustments and excess tax benefits from share-based compensation for employees.
(7)		When our senior convertible notes are dilutive on a GAAP or non-GAAP basis, net income used for calculating GAAP and non-GAAP diluted net income per share includes an interest expense add back, net of tax, under the if-converted method. In loss periods, basic and diluted net loss per share are the same since the effect of potential common shares is anti-dilutive and therefore excluded.
(8)		The adjustments are for the transition from GAAP diluted net income per share to non-GAAP diluted net income per share due to our senior convertible notes.
(9)		The sum of the non-GAAP per share components may not equal the totals due to rounding.
(10)		We adjust for the dilutive effect of our senior convertible notes when the effect is not the same on a GAAP and non-GAAP basis for a given period.

ABOUT NON-GAAP FINANCIAL MEASURES

The accompanying press release dated July 25, 2024 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, non-GAAP diluted net income per share, and non-GAAP diluted weighted average shares outstanding, as well as Adjusted EBITDA.

We report non-GAAP financial measures in addition to, and not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP. We use these non-GAAP financial measures for financial and operational decision making and period-to-period comparisons. We believe that these non-GAAP financial measures provide useful information about operating results, enhance the overall understanding of our operating performance and future prospects, and allow for greater transparency with respect to key metrics used by senior management in our financial and operational decision making. Our non-GAAP financial measures exclude amounts that we do not consider part of ongoing operating results when planning and forecasting and when assessing the performance of the organization and our senior management. While we compute non-GAAP financial measures using a consistent method from quarter to quarter and year to year, we may consider whether other significant items that arise in the future should be excluded from our non-GAAP financial measures.

These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies.

We believe that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP and that these financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand our business.

Management believes organic revenue is a meaningful metric to investors as it provides a more consistent comparison of Dexcom’s revenue to prior periods as well as to industry peers. We exclude the following items from organic revenue:

• The effect of non-CGM revenue acquired or divested in the trailing twelve months; and
• The effect of foreign currency fluctuations

Management believes that the presentation of operating results that exclude these items provides useful supplemental information to investors and facilitates the analysis of our core operating results and comparison of operating results across reporting periods. Management believes that this supplemental non-GAAP information is therefore useful to investors in analyzing and assessing our past and future operating performance.

Table E reconciles the non-GAAP financial measures included in this press release to the most directly comparable financial measures prepared in accordance with GAAP.

Our policy is to exclude the following items from non-GAAP financial measures for non-GAAP gross profit, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, and non-GAAP diluted net income per share:

• Amortization of acquired intangible assets;
• Business transition and related costs associated with acquisition and divestiture, integration and business transition activities, including severance, relocation, consulting, leasehold exit costs, third-party merger and acquisition costs, and other costs directly associated with such activities;
• Credits related to the employment of personnel during the COVID-19 pandemic;
• Income or loss from equity investments;
• Third-party intellectual property litigation costs in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc.;
• Litigation settlement costs;
• Gain or loss on extinguishment of debt; and
• Adjustments related to taxes for the excluded items above, as well as excess benefits or tax deficiencies from share-based compensation, and the quarterly impact of other discrete items

Adjusted EBITDA excludes non-cash operating charges for share-based compensation, depreciation and amortization as well as non-operating items such as interest income, interest expense, gain or loss on extinguishment of debt, income or loss from equity investments, and income tax expense or benefit. For the reasons explained above, Adjusted EBITDA also excludes business transition and related costs, COVID-19 credits, litigation settlement costs, and intellectual property litigation costs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240725250070/en/

INVESTOR RELATIONS CONTACT:

Sean Christensen

Vice President - Finance and Investor Relations

investor-relations@dexcom.com

(858) 203-6657

MEDIA CONTACT:

James McIntosh

(619) 884-2118

Source: DexCom, Inc.

FAQ

What was Dexcom's (DXCM) revenue in Q2 2024?

Dexcom's revenue in Q2 2024 was $1.004 billion, representing a 15% year-over-year growth on a reported basis.

How much did Dexcom's (DXCM) U.S. revenue grow in Q2 2024?

Dexcom's U.S. revenue grew 19% year-over-year in Q2 2024.

What is Dexcom's (DXCM) updated revenue guidance for 2024?

Dexcom updated its 2024 revenue guidance to approximately $4.00 - 4.05 billion, representing 11-13% organic growth.

What new share repurchase program did Dexcom (DXCM) announce in Q2 2024?

Dexcom announced a $750 million share repurchase program in conjunction with its Q2 2024 results.

What strategic highlights did Dexcom (DXCM) report for Q2 2024?

Dexcom launched Direct-to-Watch in the U.S. and international markets, secured coverage for Dexcom ONE in France for type 2 diabetes patients on basal insulin, and advanced pump connectivity with Insulet and Tandem Diabetes Care.